Orion Corporation, Orion Pharma
PharmaEspoo, Finland, Finland · Est. 1987 · 1,000 employees
Orion Pharma is a Finnish pharmaceutical company focused on developing and marketing specialty pharmaceuticals in neurological and psychiatric disorders.
1
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
1
Indications↗
Distinct diseases across all programs
88
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
1 drugs in development
No phase data available.
By Therapeutic Area
top 1
Oncology
1100%
R&D Momentum
18/100
Pipeline Velocity
0/100
Trial Completion Rate
93/100
Pipeline Concentration
100/100
Pipeline Freshness
45/100
Activity
Key Events
Oct 26, 2023TrialA Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
Aug 20, 2023TrialEfficacy and Tolerability of Tasipimidine in Sleepless Patients
Feb 28, 2022TrialStudy to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product
Feb 16, 2022TrialComparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler
Nov 11, 2021TrialUse of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing
May 7, 2021TrialAbsorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler
Apr 26, 2021TrialPharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler®
Dec 10, 2020TrialSwitch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
4 more events
Oct 29, 2020TrialBlood-Brain Barrier Penetration of Therapeutic Agents in Human
Nov 1, 2019TrialInspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler
Jun 26, 2019TrialEffects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
May 27, 2019TrialEffect of Charcoal on Gastrointestinal Absorption of Tiotropium
Details
Company Info
Company Overview
$2.5B
Mkt Cap
$500.0M
Revenue
—
Cash
CEOJari Sundvall
Founded1987
Employees1,000
HQEspoo, Finland, Finland
Websiteorionpharma.com
LinkedInCompany Page
Therapeutic Focus
NeurologyPsychiatryPain Management
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Oncology
Oncology
Prostate Cancer
ODM-208Phase 2
Regulatory
Regulatory Timeline
19991 event
FDAOct 19
Comtan — COMTAN
Application NDA020796 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)